122 related articles for article (PubMed ID: 28382624)
1. Cinacalcet as an alternative to phosphate therapy in X-linked hypophosphataemic rickets.
Alon US; Jarka D; Monachino PJ; Sebestyen VanSickle J; Srivastava T
Clin Endocrinol (Oxf); 2017 Jul; 87(1):114-116. PubMed ID: 28382624
[No Abstract] [Full Text] [Related]
2. Dramatic Regression of Parathyroid Gland Swelling After Conversion of Calcimimetic Medication From Cinacalcet to Etelcalcetide.
Yoshimura K; Funakoshi Y; Terawaki H
Ther Apher Dial; 2018 Oct; 22(5):553-554. PubMed ID: 29927050
[No Abstract] [Full Text] [Related]
3. Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication.
Marotta V; Di Somma C; Rubino M; Sciammarella C; Del Prete M; Marciello F; Ramundo V; Circelli L; Buonomano P; Modica R; Vitale M; Colao A; Faggiano A
Endocrine; 2015 May; 49(1):274-8. PubMed ID: 25123977
[No Abstract] [Full Text] [Related]
4. The Effectiveness of Cinacalcet as an Adjunctive Therapy for Hereditary 1,25 Dihydroxyvitamin D3-Resistant Rickets.
Akıncı A; Dündar İ; Kıvılcım M
J Clin Res Pediatr Endocrinol; 2017 Jun; 9(2):172-178. PubMed ID: 27796266
[TBL] [Abstract][Full Text] [Related]
5. Changes in bone mineral metabolism parameters, including FGF23, after discontinuing cinacalcet at kidney transplantation.
Barros X; Fuster D; Paschoalin R; Oppenheimer F; Rubello D; Perlaza P; Pons F; Torregrosa JV
Endocrine; 2015 May; 49(1):267-73. PubMed ID: 25154517
[TBL] [Abstract][Full Text] [Related]
6. A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet.
Raeder H; Shaw N; Netelenbos C; Bjerknes R
Eur J Endocrinol; 2008 Dec; 159 Suppl 1():S101-5. PubMed ID: 18775977
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review.
Yavropoulou MP; Kotsa K; Gotzamani Psarrakou A; Papazisi A; Tranga T; Ventis S; Yovos JG
Hormones (Athens); 2010; 9(3):274-8. PubMed ID: 20688626
[TBL] [Abstract][Full Text] [Related]
8. Compressive Cervical Myelopathy in X-Linked Hypophosphataemic Rickets.
Fearon C; Abbas A; Ryan SA; Fitzgerald SJ; Looby S
Can J Neurol Sci; 2018 Sep; 45(5):568-570. PubMed ID: 30032730
[No Abstract] [Full Text] [Related]
9. Complete Resolution of Tumoral Calcinosis in a Patient on Peritoneal Dialysis with Cinacalcet.
Hayat A
Perit Dial Int; 2019; 39(3):292-293. PubMed ID: 31088935
[No Abstract] [Full Text] [Related]
10. Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report.
Gonzalo García I; Robles Fradejas M; Martín Macías MLA; Biain Ciganda A; Bustinza Beaskoetxea Z; Ruiz Pérez E; Fernández Matia G; Martínez Guisasola J
J Obstet Gynaecol; 2018 Jan; 38(1):132-134. PubMed ID: 28760052
[No Abstract] [Full Text] [Related]
11. Panel Discussion: Some Aspects of the Management of Patients with X-Linked Hypophosphataemic Rickets.
Torregrosa JV; Sánchez Del Pozo J; Luiz Yanes MI; Muñoz Torres M
Adv Ther; 2020 May; 37(Suppl 2):121-126. PubMed ID: 32236878
[TBL] [Abstract][Full Text] [Related]
12. X-linked hypophosphatemic rickets and sagittal craniosynostosis: three patients requiring operative cranial expansion: case series and literature review.
Jaszczuk P; Rogers GF; Guzman R; Proctor MR
Childs Nerv Syst; 2016 May; 32(5):887-91. PubMed ID: 26510652
[TBL] [Abstract][Full Text] [Related]
13. Calcitonin administration in X-linked hypophosphatemia.
Liu ES; Carpenter TO; Gundberg CM; Simpson CA; Insogna KL
N Engl J Med; 2011 Apr; 364(17):1678-80. PubMed ID: 21524226
[No Abstract] [Full Text] [Related]
14. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
15. [Hyperphosphatasia and hypophosphatasia in childhood].
Drees P; Schmidt D; Lewens T; Vetter T; Meurer A
Orthopade; 2008 Jan; 37(1):31-9. PubMed ID: 18080109
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of patients with FGF23-related hypophosphatemic rickets.
Kinoshita Y; Saito T; Shimizu Y; Hori M; Taguchi M; Igarashi T; Fukumoto S; Fujita T
Eur J Endocrinol; 2012 Aug; 167(2):165-72. PubMed ID: 22577109
[TBL] [Abstract][Full Text] [Related]
17. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study.
Akizawa T; Shimazaki R; Fukagawa M;
PLoS One; 2018; 13(10):e0204896. PubMed ID: 30379826
[TBL] [Abstract][Full Text] [Related]
18. Burosumab treatment of children with X-linked hypophosphataemic rickets.
Gordon RJ; Levine MA
Lancet; 2019 Jun; 393(10189):2364-2366. PubMed ID: 31104830
[No Abstract] [Full Text] [Related]
19. Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism.
Ruderman I; Smith ER; Toussaint ND; Hewitson TD; Holt SG
BMC Nephrol; 2018 May; 19(1):113. PubMed ID: 29764395
[TBL] [Abstract][Full Text] [Related]
20. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.
Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S
J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
